Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 14Breast Neoplasms 3Metastatic Castration-resistant Prostate Cancer 2Carcinoma, Non-Small-Cell Lung 2Prostate Cancer Metastatic to Bone 1Prostate Adenocarcinoma 1Neoplasm Metastasis 1Multiple Myeloma 1Lung Neoplasms 1Hormone Refractory Prostate Cancer 1Bone Metastases 1

Interventions

Gemcitabine 43pembrolizumab 36Paclitaxel 36Nivolumab 31Docetaxel 29Capecitabine 29Bevacizumab 29Oxaliplatin 28Fluorouracil 28Cisplatin 26Leucovorin 24Cyclophosphamide 23Radiosurgery 20Irinotecan 20Carboplatin 20aldesleukin 19Cetuximab 19Interleukin-2 16fludarabine phosphate 15fludarabine 15Pemetrexed 15Trastuzumab 14Magnetic Resonance Spectroscopy 14Ipilimumab 14Fulvestrant 14130-nm albumin-bound paclitaxel 14Prednisone 13Everolimus 13Radiotherapy 12Panitumumab 12

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Neoplasm Metastasis × radium Ra 223 dichloride × Clear all
NCT02903160 2024-02-07

Prostate Cancer Intensive, Non-Cross Reactive Therapy (PRINT) for Castration Resistant Prostate Cancer (CRPC)

Icahn School of Medicine at Mount Sinai

Phase 2 Completed
40 enrolled 18 charts
Genitourinary

Neoplasm Metastasis, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡